Turk, B. Concentrating on proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785–799 (2006).
Edogawa, S. et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Intestine 69, 62–73 (2020).
Cenac, N. et al. Function for protease exercise in visceral ache in irritable bowel syndrome. J. Clin. Make investments. 117, 636–647 (2007).
Annahazi, A. et al. Luminal cysteine-proteases degrade colonic tight junction construction and are accountable for belly ache in constipation-predominant IBS. Am. J. Gastroenterol. 108, 1322–1331 (2013).
Denadai-Souza, A. et al. Useful proteomic profiling of secreted serine proteases in well being and inflammatory bowel illness. Sci. Rep. 8, 7834 (2018).
Galipeau, H. J. et al. Novel fecal biomarkers that precede medical prognosis of ulcerative colitis. Gastroenterology https://doi.org/10.1053/j.gastro.2020.12.004 (2020).
Klem, F. et al. Prevalence, danger elements, and outcomes of irritable bowel syndrome after infectious enteritis: a scientific assessment and meta-analysis. Gastroenterology 152, 1042–1054.e1 (2017).
Barbara, G. et al. Rome Basis Working Staff report on post-infection irritable bowel syndrome. Gastroenterology 156, 46–58.e7 (2019).
Wouters, M. M. et al. Psychological comorbidity will increase the danger for postinfectious IBS partly by enhanced susceptibility to develop infectious gastroenteritis. Intestine 65, 1279–1288 (2016).
Sundin, J. et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome sufferers correlates with mucosal lymphocyte phenotypes and psychological misery. Aliment. Pharmacol. Ther. 41, 342–351 (2015).
Jalanka-Tuovinen, J. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Intestine 63, 1737–1745 (2014).
Xu, D. et al. Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a scientific assessment and meta-analysis. Am. J. Gastroenterol. 114, 1043–1050 (2019).
El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Brathen Kristoffersen, A. & Hausken, T. Efficacy of faecal microbiota transplantation for sufferers with irritable bowel syndrome in a randomised, double-blind, placebo-controlled examine. Intestine 69, 859–867 (2020).
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M. & Moayyedi, P. Systematic assessment with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 48, 1044–1060 (2018).
Bohe, M., Borgstrom, A., Genell, S. & Ohlsson, Okay. Willpower of immunoreactive trypsin, pancreatic elastase and chymotrypsin in extracts of human feces and ileostomy drainage. Digestion 27, 8–15 (1983).
Genell, S. & Gustafsson, B. E. Impaired enteric degradation of pancreatic endopeptidases in antibiotic-treated rats. Scand. J. Gastroenterol. 12, 801–809 (1977).
Vergnolle, N. Protease inhibition as new therapeutic technique for GI ailments. Intestine 65, 1215–1224 (2016).
Galipeau, H. J. et al. Novel function of the serine protease inhibitor elafin in gluten-related problems. Am. J. Gastroenterol. 109, 748–756 (2014).
Motta, J. P. et al. Meals-grade micro organism expressing elafin defend in opposition to irritation and restore colon homeostasis. Sci. Transl. Med. 4, 158ra144 (2012).
Qin, X. Inactivation of digestive proteases by deconjugated bilirubin: the attainable evolutionary driving drive for bilirubin or biliverdin predominance in animals. Intestine 56, 1641–1642 (2007).
Pollet, R. M. et al. An atlas of beta-glucuronidases within the human intestinal microbiome. Construction 25, 967–977.e5 (2017).
He, Y. et al. Bacterial beta-glucuronidase alleviates dextran sulfate sodium-induced colitis in mice: a attainable essential new diagnostic and therapeutic goal for inflammatory bowel illness. Biochem. Biophys. Res. Commun. 513, 426–433 (2019).
Berumen, A. et al. Traits and danger elements of post-infection irritable bowel syndrome after Campylobacter enteritis. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2020.07.033 (2020).
Yoon, H. et al. Elevated pancreatic protease exercise in response to antibiotics impairs intestine barrier and triggers colitis. Cell. Mol. Gastroenterol. Hepatol. 6, 370–388 e373 (2018).
Clean, C. et al. Disseminating metaproteomic informatics capabilities and data utilizing the Galaxy-P framework. Proteomes https://doi.org/10.3390/proteomes6010007 (2018).
Easterly, C. W. et al. metaQuantome: an built-in, quantitative metaproteomics strategy reveals connections between taxonomy and protein operate in complicated microbiomes. Mol. Cell. Proteom. 18, S82–S91 (2019).
Rawlings, N. D. et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparability with peptidases within the PANTHER database. Nucleic Acids Res. 46, D624–D632 (2018).
Rolland-Fourcade, C. et al. Epithelial expression and performance of trypsin-3 in irritable bowel syndrome. Intestine 66, 1767–1778 (2017).
Jacobs, J. P. et al. A disease-associated microbial and metabolomics state in family of pediatric inflammatory bowel illness sufferers. Cell. Mol. Gastroenterol. Hepatol. 2, 750–766 (2016).
Flores, R. et al. Affiliation of fecal microbial variety and taxonomy with chosen enzymatic features. PLoS ONE 7, e39745 (2012).
Creekmore, B. C. et al. Mouse intestine microbiome-encoded beta-glucuronidases recognized utilizing metagenome evaluation guided by protein construction. mSystems https://doi.org/10.1128/mSystems.00452-19 (2019).
Macfadyen, A. & Ho, Okay. J. d-glucaro-1,4-lactone: its excretion within the bile and urine and impact on the biliary secretion of beta-glucuronidase after oral administration in rats. Hepatology 9, 552–556 (1989).
Pellock, S. J. et al. Intestine microbial beta-glucuronidase inhibition through catalytic cycle interception. ACS Cent. Sci. 4, 868–879 (2018).
Gecse, Okay. et al. Elevated faecal serine protease exercise in diarrhoeic IBS sufferers: a colonic lumenal issue impairing colonic permeability and sensitivity. Intestine 57, 591–599 (2008).
Tooth, D. et al. Characterisation of faecal protease exercise in irritable bowel syndrome with diarrhoea: origin and impact of intestine transit. Intestine 63, 753–760 (2014).
Carroll, I. M. & Maharshak, N. Enteric bacterial proteases in inflammatory bowel illness – pathophysiology and medical implications. World J. Gastroenterol. 19, 7531–7543 (2013).
Jablaoui, A. et al. Fecal serine protease profiling in inflammatory bowel ailments. Entrance. Cell. Infect. Microbiol. 10, 21 (2020).
Caminero, A. et al. Duodenal bacterial proteolytic exercise determines sensitivity to dietary antigen via protease-activated receptor-2. Nat. Commun. 10, 1198 (2019).
McCarville, J. L. et al. A commensal Bifidobacterium longum pressure prevents gluten-related immunopathology in mice via expression of a serine protease inhibitor. Appl. Environ. Microbiol. 83, e01323-17 (2017).
Parker, B. J., Wearsch, P. A., Veloo, A. C. M. & Rodriguez-Palacios, A. The genus Alistipes: intestine micro organism with rising implications to irritation, most cancers, and psychological well being. Entrance. Immunol. 11, 906 (2020).
Dziarski, R., Park, S. Y., Kashyap, D. R., Dowd, S. E. & Gupta, D. Pglyrp-regulated intestine microflora Prevotella falsenii, Parabacteroides distasonis and Bacteroides eggerthii improve and Alistipes finegoldii attenuates colitis in mice. PLoS ONE 11, e0146162 (2016).
Butera, A. et al. Nod2 deficiency in mice is related to microbiota variation favouring the growth of mucosal CD4+ LAP+ regulatory cells. Sci. Rep. 8, 14241 (2018).
Rodriguez-Palacios, A. et al. The bogus sweetener Splenda promotes intestine proteobacteria, dysbiosis, and myeloperoxidase reactivity in Crohn’s disease-like ileitis. Inflamm. Bowel Dis. 24, 1005–1020 (2018).
Genell, S., Gustafsson, B. E. & Ohlsson, Okay. Quantitation of lively pancreatic endopeptidases within the intestinal contents of germfree and traditional rats. Scand. J. Gastroenterol. 11, 757–762 (1976).
Carroll, I. M. et al. Fecal protease exercise is related to compositional alterations within the intestinal microbiota. PLoS ONE 8, e78017 (2013).
Roka, R. et al. Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice. Neurogastroenterol. Motil. 19, 57–65 (2007).
Aroniadis, O. C. et al. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 4, 675–685 (2019).
Halkjaer, S. I. et al. Faecal microbiota transplantation alters intestine microbiota in sufferers with irritable bowel syndrome: outcomes from a randomised, double-blind placebo-controlled examine. Intestine 67, 2107–2115 (2018).
Holster, S. et al. The impact of allogenic versus autologous fecal microbiota switch on signs, visceral notion and fecal and mucosal microbiota in irritable bowel syndrome: a randomized managed examine. Clin. Transl. Gastroenterol. 10, e00034 (2019).
Goll, R. et al. Results of fecal microbiota transplantation in topics with irritable bowel syndrome are mirrored by adjustments in intestine microbiome. Intestine Microbes 12, 1794263 (2020).
Smillie, C. S. et al. Pressure monitoring reveals the determinants of bacterial engraftment within the human intestine following fecal microbiota transplantation. Cell Host Microbe 23, 229–240.e5 (2018).
Mizuno, S. et al. Bifidobacterium-rich fecal donor could also be a optimistic predictor for profitable fecal microbiota transplantation in sufferers with irritable bowel syndrome. Digestion 96, 29–38 (2017).
Mkaouar, H. et al. Siropins, novel serine protease inhibitors from intestine microbiota appearing on human proteases concerned in inflammatory bowel ailments. Microb. Cell Truth. 15, 201 (2016).
Awolade, P. et al. Therapeutic significance of beta-glucuronidase exercise and its inhibitors: a assessment. Eur. J. Med. Chem. 187, 111921 (2020).
Hamoud, A. R., Weaver, L., Stec, D. E. & Hinds, T. D. Jr. Bilirubin within the liver-gut signaling axis. Tendencies Endocrinol. Metab. 29, 140–150 (2018).
Ervin, S. M. et al. Intestine microbial beta-glucuronidases reactivate estrogens as elements of the estrobolome that reactivate estrogens. J. Biol. Chem. 294, 18586–18599 (2019).
Bhatt, A. P. et al. Focused inhibition of intestine bacterial beta-glucuronidase exercise enhances anticancer drug efficacy. Proc. Natl Acad. Sci. USA 117, 7374–7381 (2020).
Wallace, B. D. et al. Construction and inhibition of microbiome beta-glucuronidases important to the alleviation of most cancers drug toxicity. Chem. Biol. 22, 1238–1249 (2015).
Koren, O. et al. Host transforming of the intestine microbiome and metabolic adjustments throughout being pregnant. Cell 150, 470–480 (2012).
Arrieta, M. C. et al. Early infancy microbial and metabolic alterations have an effect on danger of childhood bronchial asthma. Sci. Transl. Med. 7, 307ra152 (2015).
De Palma, G. et al. Transplantation of fecal microbiota from sufferers with irritable bowel syndrome alters intestine operate and habits in recipient mice. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaf6397 (2017).
Longstreth, G. F. et al. Useful bowel problems. Gastroenterology 130, 1480–1491 (2006).
Francis, C. Y., Morris, J. & Whorwell, P. J. The irritable bowel severity scoring system: a easy methodology of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 11, 395–402 (1997).
Drossman, D. A. et al. Additional validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am. J. Gastroenterol. 95, 999–1007 (2000).
Blake, M. R., Raker, J. M. & Whelan, Okay. Validity and reliability of the Bristol Stool Type Scale in wholesome adults and sufferers with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 44, 693–703 (2016).
Zigmond, A. S. & Snaith, R. P. The hospital nervousness and despair scale. Acta Psychiatr. Scand. 67, 361–370 (1983).
BBMap v. 38.73 (https://sourceforge.net/projects/bbmap/, 2019).
Hillmann, B. et al. SHOGUN: a modular, correct and scalable framework for microbiome quantification. Bioinformatics 36, 4088–4090 (2020).
Al-Ghalith, G. & Knights, D. BURST permits mathematically optimum short-read alignment for large knowledge. Preprint at bioRxiv https://doi.org/10.1101/2020.09.08.287128 (2020).
Franzosa, E. A. et al. Species-level useful profiling of metagenomes and metatranscriptomes. Nat. Strategies 15, 962–968 (2018).
Suzek, B. E., Huang, H., McGarvey, P., Mazumder, R. & Wu, C. H. UniRef: complete and non-redundant UniProt reference clusters. Bioinformatics 23, 1282–1288 (2007).
Flores, R., Shi, J., Gail, M. H., Ravel, J. & Goedert, J. J. Evaluation of the human faecal microbiota: I. Measurement and reproducibility of chosen enzymatic actions. Eur. J. Clin. Make investments. 42, 848–854 (2012).
Kursa, M. B. & Rudnicki, W. R. Function choice with the Boruta package deal. J. Stat. Softw. 36, 1–13 (2010).
Fitzpatrick, L. R. et al. Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-induced colitis following vancomycin withdrawal in mice. Intestine Pathog. 4, 13 (2012).
Dixon, P. VEGAN, a package deal of R features for group ecology. J. Veg. Sci. 14, 927–930 (2003).
Ripley, B. et al. Bundle ‘MASS’. Cran R 538, 113–120 (2013).
Chen, L. et al. GMPR: a strong normalization methodology for zero-inflated depend knowledge with utility to microbiome sequencing knowledge. Peerj https://doi.org/10.7717/peerj.4600 (2018).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery price – a sensible and highly effective strategy to a number of testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Breiman, L. Random forests. Mach. Be taught. 45, 5–32 (2001).
Robin, X. et al. pROC: an open-source package deal for R and S plus to investigate and examine ROC curves. BMC Bioinformatics https://doi.org/10.1186/1471-2105-12-77 (2011).
